A cell-therapy biotechnology company, Biostage Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), has announced today the publication of a paper in the peer-reviewed Journal of Biomechanics. This published paper describes a study investigating the mechanical strength of regenerated esophageal tissues. Biostage is a biotechnology company with a successful first-in-human experience repairing the esophagus after cancer surgery. The company has FDA approval to commence a clinical trial for Biostage Esophageal Implant for acute esophageal diseases such as cancer.
The Biostage Esophageal Implant, formerly called Cellspan Esophageal Implant, stimulates the regeneration of new tissue after segmental resection of ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals . Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer .
For further details see:
Biostage Inc Announces the Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Biomechanical Journal (BSTG)